Summary
25.69 -0.21(-0.79%)01/16/2026
Pfizer Inc. (PFE)
PFE reported last earnings on 2025-11-04 after the market. An EPS of $0.87 was observed compared to an estimated EPS of $0.633, resulting in a surprise value of $0.24. A revenue of $16,654 million was observed compared to an estimated revenue of $16,498 million, resulting in a surprise value of $156 Million.
Pfizer Inc. (PFE)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.79 | 5.20 | 5.46 | 4.82 | 12.54 | 6.78 | -12.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | A- |
| Recommended Rating | Buy |
| DCF | Strong Buy |
| ROE | Buy |
| ROA | Buy |
| Debt/Equity | Strong Sell |
| P/E | Neutral |
| P/B | Buy |
Earnings
| Trading Data | ||
| Close | 25.69 | |
| Open | 25.88 | |
| High | 25.89 | |
| Low | 25.55 | |
| Volume | 43,179,039 | |
| Change | -0.21 | |
| Change % | -0.79 | |
| Avg Volume (20 Days) | 99,952,535 | |
| Volume/Avg Volume (20 Days) Ratio | 0.43 | |
| 52 Week Range | 20.01 - 27.21 | |
| Price vs 52 Week High | -5.62% | |
| Price vs 52 Week Low | 28.35% | |
| Range | 0.00 | |
| Gap Up/Down | -0.60 | |
Profitibility | ||
| Market Capitalization (Mln) | 137,338 | |
| Revenue per share | 11.0440 | |
| Net Income per share | 1.7275 | |
| Dividend Yield | 0.0671 | |
| Dividend Share | 172.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 14.8478 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
01/19 10:06 EST - zacks.com
What to Expect From Pfizer's Non-Oncology Business in Q4?
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
What to Expect From Pfizer's Non-Oncology Business in Q4?
PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.
01/18 04:44 EST - fool.com
Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026
These five stocks offer dividend yields of up to 9.4%. They represent different sectors, including communication services, energy, financials, healthcare, and real estate.
Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026
These five stocks offer dividend yields of up to 9.4%. They represent different sectors, including communication services, energy, financials, healthcare, and real estate.
01/18 03:47 EST - defenseworld.net
Pfizer Inc. $PFE Stock Position Raised by Aviance Capital Partners LLC
Aviance Capital Partners LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 41.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 139,611 shares of the biopharmaceutical company's stock after acquiring...
Pfizer Inc. $PFE Stock Position Raised by Aviance Capital Partners LLC
Aviance Capital Partners LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 41.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 139,611 shares of the biopharmaceutical company's stock after acquiring...
01/17 08:53 EST - fool.com
The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)
All three of these companies are well established, with solid growth prospects. Each faces some struggles, but all are paying shareholders to wait for stronger results.
The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)
All three of these companies are well established, with solid growth prospects. Each faces some struggles, but all are paying shareholders to wait for stronger results.
01/16 13:08 EST - seekingalpha.com
Pfizer: Rebound Has Just Started
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield...
Pfizer: Rebound Has Just Started
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield...
01/15 08:58 EST - seekingalpha.com
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity...
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity...
01/14 18:46 EST - zacks.com
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.
01/14 08:45 EST - zacks.com
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
01/13 08:55 EST - zacks.com
Inside Pfizer's Oncology Performance Ahead of Q4 Results
PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.
Inside Pfizer's Oncology Performance Ahead of Q4 Results
PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.
01/13 07:38 EST - gurufocus.com
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals
Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt
01/13 06:11 EST - seekingalpha.com
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVID product sales and upcoming loss of exclusivity for key drugs like Eliquis and Ibrance. The $7B...
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVID product sales and upcoming loss of exclusivity for key drugs like Eliquis and Ibrance. The $7B...
01/13 02:14 EST - defenseworld.net
Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
Pfizer Inc. (NYSE: PFE - Get Free Report) has been given an average recommendation of "Hold" by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, four have...
Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts
Pfizer Inc. (NYSE: PFE - Get Free Report) has been given an average recommendation of "Hold" by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation, four have...
01/12 15:16 EST - seekingalpha.com
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01/12 13:35 EST - gurufocus.com
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Tempus Shares Jump After Strong Preliminary 2025 Results
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
01/12 05:47 EST - feeds.benzinga.com
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01/12 04:00 EST - defenseworld.net
Bristlecone Advisors LLC Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE
Bristlecone Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE: PFE) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,316 shares of the biopharmaceutical company's stock after selling...
Bristlecone Advisors LLC Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE
Bristlecone Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE: PFE) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,316 shares of the biopharmaceutical company's stock after selling...
01/10 10:00 EST - businesswire.com
Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and...
Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI (fluorouracil, leucovorin, and...
01/09 09:30 EST - fool.com
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vertex and Medtronic have attractive prospects.
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
Vertex and Medtronic could see strong momentum this year, while Pfizer is still facing challenges. Regardless of what happens in 2026, though, Vertex and Medtronic have attractive prospects.
01/09 01:52 EST - feeds.benzinga.com
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32 billion.
Market News
×
Loading news…